See the DrugPatentWatch profile for darzalex
Standard Dosing Schedule for Darzalex Faspro
Darzalex Faspro (daratumumab and hyaluronidase-fihj), used for multiple myeloma, follows a subcutaneous infusion schedule that starts intensive and tapers over time. The typical regimen is:
- Weeks 1-8 (induction phase): Weekly infusions (8 doses total).
- Weeks 9-24 (consolidation phase): Every 2 weeks (8 doses total).
- Week 25 onward (maintenance phase): Every 4 weeks, continuing until disease progression or unacceptable toxicity.
Each infusion takes about 3-5 minutes.[1]
How This Differs from Original Darzalex
Darzalex Faspro's fixed-dose subcutaneous version (1,800 mg/30 mL) replaced the original Darzalex's intravenous infusions, which lasted 3-7 hours and followed a similar weekly-to-monthly taper. No ramp-up doses are needed for Faspro.[1][2]
Adjustments for Combination Therapies
Frequency stays the same in combos like with bortezomib (VRd), lenalidomide (DRd), or pomalidomide (DPd), but align with cycle timing (e.g., every 21-28 days). In newly diagnosed patients, it may pair with RVd for 4-6 cycles before transplant.[1]
What If I Miss a Dose?
Administer the missed dose as soon as possible, then resume the original schedule. Do not double up.[1]
Monitoring and Duration
Infusions continue indefinitely or until progression/toxicity. Premedicate with steroids, antivirals, and antihistamines to reduce infusion reactions (up to 13% in trials). Regular blood tests track response.[1]
[1]: Darzalex Faspro Prescribing Information (Janssen)
[2]: DrugPatentWatch.com - Darzalex Patents and Exclusivity